Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

RESI Europe 2019 Innovation Challenge – Check Out the Winners

28 Mar

By Claire Jeong, Director of Research, Asia BD, LSN

claire

On Monday, March 25th, companies from North America, Western Europe, Israel, etc. showcased their technologies in the Vienna Marriott Hotel exhibition hall, where LSN organized the first ever (and quite successful!) RESI Europe conference. As usual, conference attendees were provided with 5 pieces of “RESI Cash” which they could use to “invest” in the companies of their choice. Again, congratulations to all finalists who were selected to present, and we hope RESI was able to serve as a great venue for creating valuable connections. But most importantly, we are excited to announce the Top 3 winners of this Innovation Challenge – please check their details below!

First Place: Rx Bandz

Rx Bandz provides a game-changing, cost-effective solution for millions of people globally who need to carry emergency injectable medication. Nearly 60% of them do not carry their prescribed auto-injectors with them. MiniJect,™ our miniaturized auto-injector, delivers a wide range of injectable drugs. Its small size and intuitive design make it easy to carry and simple to use. The first drug delivery platform for epinephrine will allow active patients to take it with them, thus increasing compliance and saving lives. Our world-class team has designed and tested a medical device that is also an attractive accessory. We have been deemed eligible for FDA- 505(B)2, the expedited pathway to market.  We have the options of either licensing the device for multiple medications, or taking it to market. Accessory attachments to the MiniJect,™ offer yet another revenue stream.

Jessica Walsh, Founder & CEO, Rx Bandz

 

Second Place: PhotoPill Medical

PhotoPill Medical develops a revolutionary state-of-the-art disposable swallow-able capsule for treating Crohn’s disease flare-ups and as a preventive treatment in-between flares, by implementing Photo-Bio-Modulation treatment (PBMt) and gut microbiota modulation light-protocols as it travels through the intestine. The PhotoPill capsule is personalized for each patient based on disease location and individual peristaltic rate. Photopill’s unique disruptive technology would be a first of its kind for intestinal tissue treatment and gut bacteria related disorders. This would be a safe, easy to use, cost effective solution for a huge market and a painful problem. PhotoPill has demonstrated excellent pre-clinical results, and preliminary data in IBD Proctitis patients, using Photopill’s dedicated rectal device. PhotoPill has strong IP portfolio and strong and experienced team.

Sharon Ben Yehuda, Co-Founder, PhotoPill Medical

 

Third Place: Pathfinder Medical

Pathfinder Medical is developing a novel electronic catheter guidance system that will enable clinicians to connect blood vessels in a minimally invasive way. This platform technology has a variety of clinical applications in peripheral vascular and dialysis procedures, together representing a €4.5 billion yearly market. Open surgery is the current standard for preparing patients for dialysis and bypassing blocked peripheral arteries. High failure rates (approximately 50%) in both cases present a serious danger to life and require repeat procedures, for US dialysis patients alone this adds up to $4.6 billion per year. The ePATH catheter platform aims to eliminate need for open surgery in several vascular procedures, improving outcomes and reducing the burden on patients and healthcare systems.

Sorin Popa, Founder & CEO, Pathfinder Medical

If you missed out on the opportunity to compete in the RESI Europe Innovation Challenge, we would be happy to take your applications for our upcoming RESI Philadelphia on Monday, June 3rd. Please visit our online application portal at http://innovchlg.lifesciencenation.com/RESIlogin.php to get your application started!

Now Offering RESI Philadelphia Early Bird Rates

Life Science Nation and Sino-American Pharmaceutical Professionals Association Team Up at RESI Philly

28 Mar

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) and the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) are announcing a joint event, bringing the SAPA-GP Venture Forum together with the Redefining Early Stage Investments (RESI) conference, taking place at the Convene in Philadelphia on June 3rd, 2019. The combined event will bring the global RESI investor and channel partner network together with the SAPA-GP community, creating a unique conference that is greater than the sum of their parts.

RESI conferences are established go-to events for fundraising CEOs, early-stage investors and channel partners that foster a fit in terms of stage of development and product with vetted investor mandates. RESI provides a matching platform to enable the vital flow of capital from investors and thereby helping emerging life science companies bring their products to market at a faster pace. RESI events are held throughout the year at major innovation hubs around the world.

RESI Philadelphia will feature a SAPA-GP Track with panel discussions, Start-up Roadshows, VC-Startup networking and Open-Table Consultations. RESI attendees will have access to this unique content, while SAPA-GP Venture Forum attendees can take advantage of the RESI panel and workshop tracks, as well as gain access to the unique RESI Partnering Forum.

LSN and SAPA-GP hope to see you at RESI Philadelphia! For any questions about SAPA-Track, please reach out to Candice He at c.he@lifesciencenation.com or WeChat: CandiceHe1028.

About SAPA-GP 

Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) is to serve the fast-growing community of pharmaceutical and biotech professionals in the Greater Philadelphia area. With a significant concentration of global pharmaceutical companies, biotech companies, and academic institutions, the greater Philadelphia area has been a center of life science discoveries and pharmaceutical innovations. Founded in 2002, SAPA-GP has established a broad-based membership and become one of the region’s premier professional organizations. It strives to bring venture investment from the U.S. and China to support the growth of the local life science entrepreneurship.

About Life Science Nation

Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early-stage scientists/entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and MedTech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early-stage life science investors and identifies who is filling the void left by venture capital. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, which brings together global early-stage biotech and MedTech companies with early-stage investors. Learn more at www.lifesciencenation.com

Call for Global Innovation

28 Mar

By Gregory Mannix, Vice President International Business Development, LSN

Once again, Life Science Nation is making a call for global life science companies to compete in the Innovation Challenge at RESI Philadelphia. We encourage companies from around the globe to complete the application to compete in this year’s edition. As is always the case, there is no cost to apply or to participate in the Challenge, and finalists will have the opportunity to present a poster at RESI designating their country of origin in the corresponding section of the Exhibition Hall. Finalists will gain excellent visibility in front of hundreds of global investors and strategics who will be attending RESI, so be sure to apply using the following link: http://innovchlg.lifesciencenation.com/RESIlogin.php

Dear Europe (V3.)

21 Mar

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On March 25th, LSN will hold the inaugural RESI Europe life science partnering conference.  Please review the program guide below, which showcases the dozens of senior investors speaking on RESI’s panels, and the startup finalists who are bringing their novel technologies to RESI’s Innovation Challenge and Pitch Challenge.

RESI is a dedicated early stage investor and channel partner conference. The event is cross silo, and brings together investors and strategic partners seeking drugs, devices, diagnostics, and digitals health technologies.  RESI is unique in that we have a one-to-one investor to fundraising CEO dynamic.

If you want to participate in the first ever RESI Europe, there’s still time to register online and participate in RESI Partnering.  We are looking forward to seeing you in Vienna on Monday.

RESI Europe Innovators‘ Pitch Challenge Finalists Announced

21 Mar

By Claire Jeong, Director of Research, Asia BD, LSN

claireOur next RESI will be landing in Vienna in just 4 days, and we are excited to announce the 5 Europe Innovators’ Pitch Challenge finalists for our inaugural Europe conference! These early-stage companies have been selected to present a short pitch to a panel of investor judges, who will provide these companies with constructive feedback.

First introduced in RESI Boston last year (September 2018), the Pitch Challenge has become a unique opportunity for the earliest stage companies, especially those who have had minimal experience in pitching and getting in front of investors. By hearing from investors and key industry partners who actively source and evaluate early-stage technologies, companies are able to improve on their pitches and work on areas of improvement more efficiently.

The Europe Innovators’ Pitch Challenge will run from 1:00 – 2:30 pm on the day of RESI and all attendees are welcome to participate as part of the audience. We look forward to seeing you there!

Moderated by Greg Mannix, VP of International Business Development at Life Science Nation, the investor panelists are:

  • Iris Öhrn, Investment Advisor – Life Sciences & Healthcare, Business Region Göteborg AB
  • Benedikt Luhmann, Principal, VI Partners
  • Andreas Jurgeit, Partner, Lundbeckfonden Emerge
  • Evan Castiglia, Principal, Philips Health Technology Ventures

And last but not least, the finalists are:

Revax

Revax is delivering revolutionary new vaccines for respiratory infections.
2019 scientific publications show that vaccines delivered to the lungs are highly effective being more effective than traditional injection vaccines and provide broader cross-reactive and long-lasting protection. Bringing together key players in aerosol delivery, academic excellence in vaccines, industrial support and clinical research organisation expertise, Revax promises to deliver a revolution in vaccination.
Advantages
* More amenable to use in children and the elderly
* Cross protective, valuable for seasonal changes in influenza and valuable for pandemics
* More effective vaccines, for example for TB
* More boostable immune responses
* Lower dose is required, reducing costs and time of manufacture, and facilitating storage and logistics issues, etc

Verde Biopharma

Medicinal cannabis is efficient – but hard to administrate – due to the challenges of THC. Verde biopharma is developing a unique set of products for pharmacies, healthcare and personal use that levels the playing field for therapeutic applications of medicinal cannabis, in a safe manner within the guidelines of the newly presented WHO recommendation for a legal rescheduling of cannabis. Our platform allows for greater individualization of medicinal cannabis products for the global market – and a practical solution to many of the challenges of the new market.

PlatOD

Platelets are blood cells which stop bleeding. The only source of platelets for transfusion is from blood donors, but there are issues of shortage, safety and efficacy. PlatOD provides an alternative to platelet transfusion from blood donors, by manufacturing platelets from stem cells using fluidic devices. With its 3 patents and know-how combining physics and biology, PlatOD has a key asset, the short duration of platelet production in its fluidic device. With its must-have technology, addressing the issue of large-scale production, PlatOD will provide the means to produce at a reasonable cost, the large volumes requested for clinical studies. The plan is to develop a pilot in 2 years, with a 4M€-fundraising.

Sumondo

We are developing a device that can help workplaces reduce costs regarding stress-related sick-leave. They can cut sick-leave expenses with 60% and increase work productivity. From our device, the employees get biofeedback and learn what their stress-level is. The management can collect the data and show it on a common dashboard. Interventions should be made and their effect can be measured before and after. We measure 24/7, also during sleep and can give early warnings about emerging toxic, chronic stress, which woul lead to severe illness, long-time absence and inability to work. Our main target are workplaces. A secondary target are hospitals which we can help reduce stress and provide early warnings about severe developments in the patients with cardio-vascular diseases.

Iluria Health

Iluria is a digital health company focusing on ADHD. In a nutshell, we aim to solve the current trial and error ongoing treatment in ADHD patients. We are doing so through an ML based solution which provides on-going, personalized & passive ADHD monitoring, using biomarkers data (wearable agnostic) and AI analysis.

Exploring the Digital Future of Healthcare: Digital Health Investors Panel at RESI Europe

21 Mar

By Karen Deyo, Investor Research Analyst, LSN

Despite the relatively short span of time digital health, as a sector, has been in existence, there has been an explosion in technology and applications in recent years. The increase in digital applications and services, for providers, payers and consumers, is so pronounced, that governments are scrambling to keep up and provide some sort of regulatory framework that can apply to these cutting-edge technologies. From patient disease management to AI-powered diagnostics to EHR management to care coordination, the diversity within digital health can make it difficult to speak to the sector as a whole.

Addressing some of these questions at RESI Europe, the speakers on the Digital Health Investors panel will share their expertise in this area. The panel will take place from 9:00-9:50 AM, and we recommend that anyone interested in an investor’s perspective on the field of digital health attend!

Moderator: Jonas Jendi (Investment Manager, Industrifonden)

Jonas Jendi is an investment manager at Nordic VC Industrifonden (Stockholm), focused on the life science sector. Industrifonden is one of the largest VC funds in the Nordics, focusing on both tech and life science. The €500m evergreen fund invests in early-stage ventures. The Industrifonden life science team currently has a portfolio of 14 companies, from medtech to biotech, both private and publicly traded. Jonas joined Industrifonden in May 2017, bringing onboard recent experience as an independent board member, angel investor and equity analyst. Between 2001 and 2010, Jonas was CEO at Cogmed, a start-up in the field of evidence-based cognitive training (clinically validated software), based in Stockholm and later in the US. Jonas took the company from the research phase at Karolinska Institute in 2001 to acquisition by Pearson in 2010, then managing the Cogmed integration into Pearson. His background also includes strategy work with The Boston Consulting Group.

Lara Koole (Principal, Philips Health Technology Ventures)

Lara leads the European venture capital activities for Philips, includes running the business-independent Philips health technology venture fund focused on investments in early-stage digital health companies to drive strategic value-add relationships with Philips. Looking for driven entrepreneurs that are passionate and capable to address (part of) the quadruple aim in healthcare, improving outcomes and lowering costs while increasing patient and staff satisfaction. Passionate about technology, strategic investing and working together with great teams to scale their companies bringing strategic and industry expertise of Philips to the table.

Tony Chang (Associate, M Ventures)

Tony Chang, PhD, MBA, is an Investment Associate with the New Businesses team at M Ventures. In this role, Tony is focusing on the early stage venture deals in health-tech and digital health, with a particular attention on digital therapeutics deals. Tony has developed substantial experience in assessing digital health deals for both in-clinic and out-of-clinic applications. Prior to M Ventures, Tony was a technology commercialization officer at the University of Western Cape in South Africa where he was responsible for the development of several industry research collaboration and licensing deals. Previously, Tony was a consultant at the strategy practice of EY in Johannesburg.

Thomas Walbert (Digital Health Innovation Manager, weXelerate)

Stephen Kearney is a medical doctor, working with Hannover Re, one of the world’s largest reinsurers. Stephen’s medical speciality is surgery, with experience in academic pathology via lecturing and research, having specialised in cancer genomics and medical informatics. Approximately half of Hannover Re’s business is in the life and health (re)insurance space. Within these verticals, Stephen’s responsibilities include identifying and developing both internal and external innovation opportunities, including in the area of genomics. Besides medicine, Stephen also has academic qualifications and experience in computer science, data analytics and pharmaceutical business, and an undergraduate degree in biochemistry and physics from University College Dublin (UCD).

Stephen Kearney (Innovation – Life & Health, Hannover Re)

Thomas Walbert is the Digital Health Innovation Manager at weXelerate, where he is responsible for building the Health-Cluster program for fostering digital health innovation and managing a network of mentors and experts. Previously, Thomas was a Start-up Consultant at INiTS, a high-tech incubator based in Vienna. He is a start-up enthusiast who is experienced in building environments and networks where corporations and high-tech start-ups can launch revolutionary business models, products, and services.

RESI Europe Innovation Challenge – Meet the Startup Finalists

14 Mar

By Karen Deyo, Investor Research Analyst, LSN

The inaugural RESI Europe is just around the corner, and with that, we are happy to announce the finalists for the RESI Innovation Challenge. On March 25th in Vienna, these finalists will present posters of their technologies in the Exhibition Hall. From therapeutics to devices, diagnostics to digital health, the technologies are as diverse as the countries these companies represent, with startups participating from all over Europe, Israel and even from the US. We encourage all attendees to take the opportunity to check out all of these companies and their technologies and to “invest” your “RESI cash” in your favorite(s). The top three companies will receive prizes at the end of the day, so make sure to go through the exhibition hall and cast your votes!

Thank you to all of the companies that submitted applications to the Innovation Challenge – we encourage you to try again at a future RESI. Good luck to the finalists, and we look forward to seeing you in Vienna!

Therapeutic

 

Diagnostic

 

MedTech Device

 

Digital Health

← Older Entries
Newer Entries →